196 related articles for article (PubMed ID: 25669975)
101. Role of the fibroblast growth factor receptor axis in cholangiocarcinoma.
Ang C
J Gastroenterol Hepatol; 2015 Jul; 30(7):1116-22. PubMed ID: 25678238
[TBL] [Abstract][Full Text] [Related]
102. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience.
Sholl LM; Aisner DL; Varella-Garcia M; Berry LD; Dias-Santagata D; Wistuba II; Chen H; Fujimoto J; Kugler K; Franklin WA; Iafrate AJ; Ladanyi M; Kris MG; Johnson BE; Bunn PA; Minna JD; Kwiatkowski DJ;
J Thorac Oncol; 2015 May; 10(5):768-777. PubMed ID: 25738220
[TBL] [Abstract][Full Text] [Related]
103. HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomas.
Reis H; Herold T; Ting S; Worm K; Huber U; Christoph DC; Eberhardt WE; Kostbade K; Kasper S; Stamatis G; Welter S; Darwiche K; Karpf-Wissel R; Theegarten D; Schmid KW; Schuler M; Wiesweg M
Lung Cancer; 2015 Apr; 88(1):34-41. PubMed ID: 25708529
[TBL] [Abstract][Full Text] [Related]
104. Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options.
Ross JS; Badve S; Wang K; Sheehan CE; Boguniewicz AB; Otto GA; Yelensky R; Lipson D; Ali S; Morosini D; Chliemlecki J; Elvin JA; Miller VA; Stephens PJ
Arch Pathol Lab Med; 2015 May; 139(5):642-9. PubMed ID: 25927147
[TBL] [Abstract][Full Text] [Related]
105. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Rizvi NA; Hellmann MD; Snyder A; Kvistborg P; Makarov V; Havel JJ; Lee W; Yuan J; Wong P; Ho TS; Miller ML; Rekhtman N; Moreira AL; Ibrahim F; Bruggeman C; Gasmi B; Zappasodi R; Maeda Y; Sander C; Garon EB; Merghoub T; Wolchok JD; Schumacher TN; Chan TA
Science; 2015 Apr; 348(6230):124-8. PubMed ID: 25765070
[TBL] [Abstract][Full Text] [Related]
106. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.
Blumenschein GR; Smit EF; Planchard D; Kim DW; Cadranel J; De Pas T; Dunphy F; Udud K; Ahn MJ; Hanna NH; Kim JH; Mazieres J; Kim SW; Baas P; Rappold E; Redhu S; Puski A; Wu FS; Jänne PA
Ann Oncol; 2015 May; 26(5):894-901. PubMed ID: 25722381
[TBL] [Abstract][Full Text] [Related]
107. A Pan-Cancer Review of ALK Mutations: Implications for Carcinogenesis and Therapy.
Yau NK; Fong AY; Leung HF; Verhoeft KR; Lim QY; Lam WY; Wong IC; Lui VW
Curr Cancer Drug Targets; 2015; 15(4):327-36. PubMed ID: 25714698
[TBL] [Abstract][Full Text] [Related]
108. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
[TBL] [Abstract][Full Text] [Related]
109. FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors.
Li F; Huynh H; Li X; Ruddy DA; Wang Y; Ong R; Chow P; Qiu S; Tam A; Rakiec DP; Schlegel R; Monahan JE; Huang A
Cancer Discov; 2015 Apr; 5(4):438-51. PubMed ID: 25673643
[TBL] [Abstract][Full Text] [Related]
110. P53 mutations occur more commonly than KRAS mutations in colorectal adenoma.
Yan WF; Wu G; Sun PC; Qiu D
Int J Clin Exp Med; 2015; 8(1):1370-5. PubMed ID: 25785139
[TBL] [Abstract][Full Text] [Related]
111. Occurrence of low frequency PIK3CA and AKT2 mutations in gastric cancer.
Zhang QY; Cheng WX; Li WM; Au W; Lu YY
Mutat Res; 2014 Nov; 769():108-12. PubMed ID: 25771729
[TBL] [Abstract][Full Text] [Related]
112. Evaluation of Trastuzumab Anti-Tumor Efficacy and its Correlation with HER-2 Status in Patient-Derived Gastric Adenocarcinoma Xenograft Models.
Chen H; Ye Q; Lv J; Ye P; Sun Y; Fan S; Su X; Gavine P; Yin X
Pathol Oncol Res; 2015 Sep; 21(4):947-55. PubMed ID: 25749810
[TBL] [Abstract][Full Text] [Related]
113. Progression of naive intraepithelial neoplasia genome to aggressive squamous cell carcinoma genome of uterine cervix.
Jung SH; Choi YJ; Kim MS; Baek IP; Lee SH; Lee AW; Hur SY; Kim TM; Lee SH; Chung YJ
Oncotarget; 2015 Feb; 6(6):4385-93. PubMed ID: 25738363
[TBL] [Abstract][Full Text] [Related]
114. Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy.
Rose PG; Java J; Whitney CW; Stehman FB; Lanciano R; Thomas GM; DiSilvestro PA
J Clin Oncol; 2015 Jul; 33(19):2136-42. PubMed ID: 25732170
[TBL] [Abstract][Full Text] [Related]
115. Metastatic Extramammary Paget's Disease of Scrotum Responds Completely to Single Agent Trastuzumab in a Hemodialysis Patient: Case Report, Molecular Profiling and Brief Review of the Literature.
Barth P; Dulaimi Al-Saleem E; Edwards KW; Millis SZ; Wong YN; Geynisman DM
Case Rep Oncol Med; 2015; 2015():895151. PubMed ID: 25692060
[TBL] [Abstract][Full Text] [Related]
116. Study of efflux pump gene expression in rifampicin-monoresistant Mycobacterium tuberculosis clinical isolates.
Li G; Zhang J; Guo Q; Wei J; Jiang Y; Zhao X; Zhao LL; Liu Z; Lu J; Wan K
J Antibiot (Tokyo); 2015 Jul; 68(7):431-5. PubMed ID: 25690361
[TBL] [Abstract][Full Text] [Related]
117. Metabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer.
Shi S; Ji S; Qin Y; Xu J; Zhang B; Xu W; Liu J; Long J; Liu C; Liu L; Ni Q; Yu X
Cancer Lett; 2015 May; 360(2):227-33. PubMed ID: 25687883
[TBL] [Abstract][Full Text] [Related]
118. Prognostic significance of systemic neutrophil and leukocyte alterations in surgically treated endometrial cancer patients: a monoinstitutional study.
Takahashi R; Mabuchi S; Kawano M; Sasano T; Matsumoto Y; Kuroda H; Hisamatsu T; Kozasa K; Sawada K; Hamasaki T; Kimura T
Gynecol Oncol; 2015 Apr; 137(1):112-8. PubMed ID: 25680864
[TBL] [Abstract][Full Text] [Related]
119. Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W.
Chae YK; Hong F; Vaklavas C; Cheng HH; Hammerman P; Mitchell EP; Zwiebel JA; Ivy SP; Gray RJ; Li S; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Mansfield A; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
J Clin Oncol; 2020 Jul; 38(21):2407-2417. PubMed ID: 32463741
[TBL] [Abstract][Full Text] [Related]
120. Novel therapeutic strategy for cervical cancer harboring FGFR3-TACC3 fusions.
Tamura R; Yoshihara K; Saito T; Ishimura R; Martínez-Ledesma JE; Xin H; Ishiguro T; Mori Y; Yamawaki K; Suda K; Sato S; Itamochi H; Motoyama T; Aoki Y; Okuda S; Casingal CR; Nakaoka H; Inoue I; Verhaak RGW; Komatsu M; Enomoto T
Oncogenesis; 2018 Jan; 7(1):4. PubMed ID: 29358619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
